Earnings Call Summary | PaySign(PAYS.US) Q1 2024 Earnings Conference
Earnings Call Summary | PaySign(PAYS.US) Q1 2024 Earnings Conference
The following is a summary of the Paysign, Inc. (PAYS) Q1 2024 Earnings Call Transcript:
以下是Paysign, Inc.（PAYS）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Paysign reported Q1 2024 revenue of $13.2 million, marking a 30% increase year-over-year.
Paysign's adjusted EBITDA increased by 135% to $1.7 million, or $0.03 per fully diluted share, up from $720,000 in the previous year.
Gross dollar load volume and gross spend volume rose by 13% and 11% respectively.
The Patient Affordability business contributed to 59% of the total year-over-year revenue growth with a 305% increase in revenue.
Paysign报告称，2024年第一季度收入为1,320万美元，同比增长30％。
Paysign调整后的息税折旧摊销前利润从去年的72万美元增长了135％，至170万美元，摊薄后每股收益为0.03美元。
美元总负荷量和总支出量分别增长了13％和11％。
患者负担能力业务贡献了总收入同比增长的59％，收入增长了305％。
Business Progress:
业务进展：
Paysign expanded its patient affordability programs to reach a total of 53 active programs.
An entrance into retail drug programs with 4 programs added in Q1 and more expected to launch in the future.
The plasma donor compensation business saw an 11% increase in revenue.
The company anticipates adding 15 to 25 new plasma donor centers in 2024.
Paysign is seeking to enter new markets while also investing in its personnel and systems to meet growing demand.
Paysign将其患者负担能力计划扩展到总共53个活跃计划。
零售药品计划的入口，第一季度增加了4个项目，预计将来还会推出更多项目。
血浆捐赠者补偿业务的收入增长了11％。
该公司预计，2024年将增加15至25个新的血浆捐赠中心。
Paysign正在寻求进入新市场，同时还投资其人员和系统，以满足不断增长的需求。
More details: PaySign IR
更多详情： PaySign IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。